TabsDetailsBasic DetailsDate Posted: Wednesday, January 24, 2018Status: CompleteMedical Product: axitinib, bicalutamide, crizoatinib, dasatinib, erlotinib HCL, everolimus, gefitinib, imatinib mesylate, lapatinib ditosylate, nilotinib HCL, pazopanib HCL, ruxolitinib phosphate, sorafenib tosylate, sunitinib malate, tamoxifen citrate, vandetanib, vemurafenib, vismodegibDescription: These reports look at the use of 18 selected generic drug products relating to molecularly targeted anti-cancer therapies in the Mini-Sentinel Distributed Database (MSDD). These results were generated using the Mini-Sentinel Distributed Query Tool. This query was run against the Dispensing Summary Table and distributed on May 10, 2013 to 17 Data Partners; this report includes information from 17 Data Partners. Read More Deliverables (2)Mini-Sentinel Summary Table Report: Molecularly Targeted Anti-Cancer Therapies Report 1Mini-Sentinel Summary Table Report: Molecularly Targeted Anti-Cancer Therapies Report 2Additional InformationAdditional DetailsFDA Center: CDERTime Period: 2000 - 2012Study Type: Summary TableAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Mini-Sentinel Distributed Database (MSDD)